Literature DB >> 6176454

Intersubject variability in the anticoagulant response to heparin in vitro.

T D Bjornsson, K M Wolfram.   

Abstract

The significance of baseline coagulation times and plasma concentrations of serine protease inhibitors as determinants of the relationship between heparin activity and its anticoagulant effect has been investigated in vitro. Citrated plasma was prepared from blood obtained from 20 normal subjects, and heparin added to yield concentrations ranging from 0.05 to 1.5 units/ml. The anticoagulant effect was determined by the activated partial thromboplastin time (APTT) and thrombin time (TT). An excellent linear relationship was observed between the natural logarithms (ln) of the coagulation times and heparin activity. Baseline APTT values ranged from 28.4 to 59.7 s and the slope values for the ln APTT vs heparin curves ranged from 1.488 to 3.427 ml/unit. Similar range was observed in the slope values for the ln TT vs heparin curves. There was a highly significant positive correlation between the ln APTT vs heparin slope values and the baseline APTT values (r: 0.905; p less than 0.001). There was also a weak but statistically significant positive correlation between plasma concentrations of alpha 2 macroglobulin and baseline APTT values (0.02 greater than 0 greater than 0.01) and slope values of the ln APTT vs heparin curves (0.02 greater than p greater than 0.01). Furthermore, there was a statistically significant positive correlation between plasma concentrations of alpha 1 antitrypsin and baseline TT values (0.05 greater than p greater than 0.02) and slope values of the 1n TT vs heparin (0.02 greater than p greater than 0.01). Neither baseline APTT and TT values nor slope values of the ln APTT and TT vs heparin curves were statistically significantly related to plasma concentrations of antithrombin III, fibrinogen, or alpha 1 acid glycoprotein. This study has demonstrated that baseline APTT is a major determinant of the anticoagulant response to heparin in vitro, as determined by that same coagulation test, and it illustrates that there is a wide intersubject variation in the anticoagulant response to heparin in vitro.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6176454     DOI: 10.1007/BF00542044

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  20 in total

1.  INHERITED ANTITHROMBIN DEFICIENCY CAUSING THROMBOPHILIA.

Authors:  O EGEBERG
Journal:  Thromb Diath Haemorrh       Date:  1965-06-15

2.  The relationship between heparin dosage and clotting time.

Authors:  L B JAQUES; A G RICKER
Journal:  Blood       Date:  1948-10       Impact factor: 22.113

3.  Interaction of thrombin with antithrombin III and alpha macroglobulin in the plasma.

Authors:  A Takada; T Koide; Y Takada
Journal:  Thromb Res       Date:  1979       Impact factor: 3.944

4.  Pharmacokinetics of heparin. I. Studies of dose dependence in rats.

Authors:  T D Bjornsson; G Levy
Journal:  J Pharmacol Exp Ther       Date:  1979-08       Impact factor: 4.030

5.  Familial thrombosis due to antithrombin 3 deficiency.

Authors:  E Marciniak; C H Farley; P A DeSimone
Journal:  Blood       Date:  1974-02       Impact factor: 22.113

6.  The heterogeneity of the anticoagulant response to heparin.

Authors:  J W Estes
Journal:  J Clin Pathol       Date:  1972-01       Impact factor: 3.411

7.  A prospective study of the value of monitoring heparin treatment with the activated partial thromboplastin time.

Authors:  D Basu; A Gallus; J Hirsh; J Cade
Journal:  N Engl J Med       Date:  1972-08-17       Impact factor: 91.245

8.  Inhibition of the thrombin-fibrinogen reaction by heparin and purified cofactor.

Authors:  U Abildgaard
Journal:  Scand J Haematol       Date:  1968

9.  Heparin kinetics in venous thrombosis and pulmonary embolism.

Authors:  J Hirsh; W G van Aken; A S Gallus; C T Dollery; J F Cade; W L Yung
Journal:  Circulation       Date:  1976-04       Impact factor: 29.690

10.  Relationship between concentration and anticoagulant effect of heparin in plasma of normal subjects: magnitude and predictability of interindividual differences.

Authors:  L R Whitfield; G Levy
Journal:  Clin Pharmacol Ther       Date:  1980-10       Impact factor: 6.875

View more
  6 in total

1.  Application of Adaptive DP-optimality to Design a Pilot Study for a Clotting Time Test for Enoxaparin.

Authors:  Abhishek Gulati; James M Faed; Geoffrey K Isbister; Stephen B Duffull
Journal:  Pharm Res       Date:  2015-07-01       Impact factor: 4.200

2.  Investigations on plasma activity of low molecular weight heparin after intravenous and oral administrations.

Authors:  M Dryjski; D E Schneider; P Mojaverian; B S Kuo; T D Bjornsson
Journal:  Br J Clin Pharmacol       Date:  1989-08       Impact factor: 4.335

3.  Guidelines to control heparin treatment.

Authors:  A G Fennerty; S Renowden; N Scolding; D P Bentley; I A Campbell; P A Routledge
Journal:  Br Med J (Clin Res Ed)       Date:  1986-03-01

4.  Assay-dependent kinetics of heparin: evidence for rapid in vivo activation of heparin.

Authors:  F X McGowan; P V Nash; T D Bjornsson
Journal:  Br J Clin Pharmacol       Date:  1983-12       Impact factor: 4.335

Review 5.  Pharmacokinetic optimisation of the treatment of deep vein thrombosis.

Authors:  A Iorio; G Agnelli
Journal:  Clin Pharmacokinet       Date:  1997-02       Impact factor: 6.447

Review 6.  Heparin pharmacokinetics and pharmacodynamics.

Authors:  R J Kandrotas
Journal:  Clin Pharmacokinet       Date:  1992-05       Impact factor: 6.447

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.